caa a22 4500 477129218 CHVBK 20180405111659.0 cr unu---uuuuu 170330e19970701xx s 000 0 eng 10.1023/A:1018450531136 doi (NATIONALLICENCE)springer-10.1023/A:1018450531136 Serum levels of vitamin D metabolites and the subsequent risk of colon and rectal cancer in Finnish men [Elektronische Daten] [Joseph Tangrea, Kathy Helzlsouer, Pirjo Pietinen, Philip Taylor, Bruce Hollis, Jarmo Virtamo, Demetrius Albanes] Experimental and human epidemiologic data suggest a protective rolefor vitamin D in large bowel cancer. To investigate this association, weconducted a nested case-control study within a Finnish clinical trial cohort.Cases (n = 146) were participants diagnosed with primary adenocarcinoma ofthe large bowel. Controls were matched (2:1) to cases on age, date ofbaseline blood draw, and study clinic. Prediagnostic serum levels of thevitamin D metabolites, 25-hydroxyvitamin D (25-OH D), and1,25-dihydroxyvitamin D (1,25-DIOHD) were used as primary exposure measures.The baseline geometric-mean serum level of 25-OH D was 11.6 percent lower incases than in controls (12.2 cf 13.8 ug/l, P = 0.01) while serum levels of1,25-DIOH D did not differ by case-control status. No association was seenbetween serum levels of 1,25-DIOH D and large bowel cancer risk. However, theestimated relative risk (RR) of large bowel cancer decreased with increasinglevel of serum 25-OH D and the associa tion was more pronounced for rectalcancer (55 cases; RR by quartile = 1.00, 0.93, 0.77, 0.37; trend P = 0.06).Neither exclusion of early cases nor multivariate adjustment for potentialconfounders materially altered these estimates. There was no evidence ofeffect modification by level of 1,25-dihydroxyvitamin D or with other knownrisk-factors for large bowel cancer. Chapman and Hall, 1997 25-hydroxyvitamin D nationallicence colorectal cancer nationallicence Finland nationallicence men nationallicence rectal cancer nationallicence vitamin D nationallicence Tangrea Joseph National Cancer Institute, NIH, Bethesda, USA aut Helzlsouer Kathy School of Hygiene and Public Health, Johns Hopkins Universitycty, Baltimore, USA aut Pietinen Pirjo National Public Health Institute, Helsinki, USA aut Taylor Philip National Cancer Institute, NIH, Bethesda, USA aut Hollis Bruce Medical University of South Carolina, Charleston, USA aut Virtamo Jarmo National Cancer Institute, NIH, Bethesda, USA aut Albanes Demetrius National Cancer Institute, NIH, Bethesda, USA aut Cancer Causes & Control Kluwer Academic Publishers 8/4(1997-07-01), 615-625 0957-5243 8:4<615 1997 8 10552 https://doi.org/10.1023/A:1018450531136 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1023/A:1018450531136 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Tangrea Joseph National Cancer Institute, NIH, Bethesda, USA aut NATIONALLICENCE 700 1- Helzlsouer Kathy School of Hygiene and Public Health, Johns Hopkins Universitycty, Baltimore, USA aut NATIONALLICENCE 700 1- Pietinen Pirjo National Public Health Institute, Helsinki, USA aut NATIONALLICENCE 700 1- Taylor Philip National Cancer Institute, NIH, Bethesda, USA aut NATIONALLICENCE 700 1- Hollis Bruce Medical University of South Carolina, Charleston, USA aut NATIONALLICENCE 700 1- Virtamo Jarmo National Cancer Institute, NIH, Bethesda, USA aut NATIONALLICENCE 700 1- Albanes Demetrius National Cancer Institute, NIH, Bethesda, USA aut NATIONALLICENCE 773 0- Cancer Causes & Control Kluwer Academic Publishers 8/4(1997-07-01), 615-625 0957-5243 8:4<615 1997 8 10552 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer